Systematic evaluation re-evaluation of Kangai injection in combination with chemotherapy for non-small cell lung cancer
Download as PDF
Debo Xu, Dongqing Pu, Taiying Li, Yue Wu, Lingyuan Kong, Zhongqi Zhou
To evaluate the methodological quality and evidence quality of the existing systematic evaluation of Kangai injection combined with chemotherapy for non-small cell lung cancer (NSCLC), the databases of China Knowledge Network (CNKI), Wanfang Database, China Biomedical Literature Database (CBM), VIP, PubMed, Embase, Cochrane Library, and Web of Science were searched for systematic evaluations of Kangai injection in combination with chemotherapy for NSCLC from database creation to April 2022. Two investigators independently screened the literature, extracted information, used the PRISMA statement to evaluate the report quality of included studies, the AMSTAR2 scale to assess the methodological quality, and the GRADE system to assess the level of evidence. A total of 10 systematic evaluations were included, with PRISMA statement evaluations showing four scores of 21.5-27, five scores of 15.5-21, and one score of 15 or less. The AMSTAR2 review indicated one study with low methodological quality and nine studies with deficient methodological quality. The GRADE evaluation showed moderate evidence for six indicators, scarce evidence for 32 indicators, and deficient evidence for 31 indicators. The efficacy and safety of Kangai injection combined with chemotherapy for non-small cell lung cancer are superior to chemotherapy alone; however, the methodological quality of the current systematic evaluations and the quality of evidence is low.
Kangai injection; non-small cell lung cancer; systematic evaluation re-evaluation; AMSTAR2 scale; GRADE system